Polycystic ovary syndrome in the Indian Subcontinent

ABSTRACT

Polycystic ovary syndrome (PCOS) is a complex, multifaceted, heterogeneous disorder that affects ~5 to 10% of women of reproductive age. It is characterized by hyperandrogenism, polycystic ovaries, and chronic anovulation along with insulin resistance, hyperinsulinemia, abdominal obesity, hypertension, and dyslipidemia as frequent metabolic traits (metabolic syndrome) that culminate in serious long-term consequences such as type 2 diabetes mellitus, endometrial hyperplasia, and coronary artery disease. It is one of the most common causes of anovulatory infertility. However, the heterogeneous clinical features of PCOS may change throughout the life span, starting from adolescence to postmenopausal age, largely influenced by obesity and metabolic alterations, and the phenotype of women with PCOS is variable, depending on the ethnic background.

The etiology of PCOS is yet to be elucidated; however, it is believed that in utero fetal programming may have a significant role in the development of PCOS phenotype in adult life. Though a woman may be genetically predisposed to developing PCOS, it is only the interaction of environmental factors (obesity) with the genetic factors that results in the characteristic metabolic and menstrual disturbances and the final expression of the PCOS phenotype.

Irrespective of geographic locations, a rapidly increasing prevalence of polycystic ovarian insulin resistance syndrome, excess body fat, adverse body fat patterning, hypertriglyceridemia, and obesity-related disease, such as diabetes and cardiovascular disease, have been reported in Asian Indians, suggesting that primary prevention strategies should be initiated early in this ethnic group. In lieu of the epidemic increase in the prevalence of obesity and diabetes mellitus in most industrialized countries including China and India owing to Westernization, urbanization, and mechanization, and evidence suggesting a pathogenetic role of obesity in the development of PCOS and related infertility, active intervention to combat the malice of these disorders is warranted. Pharmacologic therapy is a critical step in the management of patients with metabolic syndrome when lifestyle modifications fail to achieve the therapeutic goals, and studies in China and India have proved to be effective.

KEYWORDS

Polycystic ovary syndrome - Indian subcontinent - ethnicity - Asian Indians - India

REFERENCES

• 1 Sheikhha M H, Kalantar S M. Diagnostic criteria in polycystic ovary syndrome. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 27-32
• 2 Balen A H, Dunger D. Pubertal maturation of the internal genitalia.  Ultrasound Obstet Gynecol. 1995;  6 164-165
• 3 Elting M W, Korsen T JM, Rekers-Mombarg L TM, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing.  Hum Reprod. 2000;  15 24-28
• 4 Zawadzki J A, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR Polycystic Ovary Syndrome. Boston, MA; Blackwell Scientific 1992: 377-384
• 5 Polson D W, Adams J, Wadsworth J, Franks S. Polycystic ovaries - a common finding in normal women.  Lancet. 1988;  1 870-872
• 6 Rodin D A, Bano G, Bland J M, Taylor K, Nussey S S. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women.  Clin Endocrinol (Oxf). 1998;  49 91-99
• 7 Zargar A H, Gupta V K, Wani A I et al.. Prevalence of ultrasonography proved polycystic ovaries in North Indian women with type 2 diabetes mellitus.  Reprod Biol Endocrinol. 2005;  3 35-41
• 8 Wijeyaratne C N, Balen A H, Barth J H, Belchetz P E. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference?.  Clin Endocrinol (Oxf). 2002;  57 343-350
• 9 Charnvises K, Weerakiet S, Tingthanatikul Y, Wansumrith S, Chanprasertyothin S, Rojanasakul A. Acanthosis nigricans: clinical predictor of abnormal glucose tolerance in Asian women with polycystic ovary syndrome.  Gynecol Endocrinol. 2005;  21 161-164
• 10 Franks S. Polycystic ovary syndrome.  N Engl J Med. 1995;  333 853-861
• 11 Carmina E, Koyama T, Chang L, Stanczyk F Z, Lobo R A. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?.  Am J Obstet Gynecol. 1992;  167 1807-1812
• 12 Zargar A H, Wani A I, Masoodi S R, Laway B A, Bashir M I, Salahuddin M. Epidemiologic and etiologic aspects of hirsutism in Kashmiri women in the Indian subcontinent.  Fertil Steril. 2002;  77 674-678
• 13 Bigazzi R, Bianchi S. Insulin resistance, metabolic syndrome and endothelial dysfunction.  J Nephrol. 2007;  20 10-14
• 14 Vignesh J P, Mohan V. Polycystic ovary syndrome: a component of metabolic syndrome?.  J Postgrad Med. 2007;  53 128-134
• 15 Jialal I, Naiker P, Reddi K, Moodley J, Joubert S M. Evidence for insulin resistance in nonobese patients with polycystic ovarian disease.  J Clin Endocrinol Metab. 1987;  64 1066-1069
• 16 Sundararaman P G, Manomani R, Sridhar G R, Sridhar V, Sundaravalli A, Umachander M. Risk of atherosclerosis in women with polycystic ovary syndrome: a study from South India.  Metabolic Syndrome and Related Disorders.. 2003;  1 271-275
• 17 Kaushal R, Parchure N, Bano G, Kaski J C, Nussey S S. Insulin resistance and endothelial dysfunction in the brothers of Indian subcontinent Asian women with polycystic ovaries.  Clin Endocrinol (Oxf). 2004;  60 322-328
• 18 Deedwania P C, Gupta R. Management issues in the metabolic syndrome.  J Assoc Physicians India. 2006;  54 797-810
• 19 Yoon K H, Lee J H, Kim J W et al.. Epidemic obesity and type 2 diabetes in Asia.  Lancet. 2006;  368 1681-1688
• 20 Gupta A, Gupta R, Sarna M, Rastogi S, Gupta V P, Kothari K. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population.  Diabetes Res Clin Pract. 2003;  61 69-76
• 21 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.  J Clin Endocrinol Metab. 1999;  84 165-169
• 22 Weerakiet S, Srisombut C, Rojanasakul A, Panburana P, Thakkinstian A, Herabutya Y. Prevalence of gestational diabetes mellitus and pregnancy outcomes in Asian women with polycystic ovary syndrome.  Gynecol Endocrinol. 2004;  19 134-140
• 23 Park K H, Kim J Y, Ahn C W, Song Y D, Lim S K, Lee H C. Polycystic ovarian syndrome (PCOS) and insulin resistance.  Int J Gynaecol Obstet. 2001;  74 261-267
• 24 Ek I, Arner P, Bergqvist A, Carlstrom K, Wahrenberg H. Impaired adipocyte lipolysis in nonobese women with the polycystic ovary syndrome: a possible link to insulin resistance?.  J Clin Endocrinol Metab. 1997;  82 1147-1153
• 25 Norman R J, Masters L, Milner C R, Wang X J, Davies M J. Relative risk of conversion from normoglycemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.  Hum Reprod. 2001;  16 1995-1998
• 26 Borch-Johnsen K. The metabolic syndrome in a global perspective. The public health impact-secondary publication.  Dan Med Bull. 2007;  54 157-159
• 27 Zeyneloglu H B, Esinler I. Chronic complications of polycystic ovary syndrome. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 102-112
• 28 Apridonidze T, Essah P A, Iuorno M J, Nestler J E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2005;  90 1929-1935
• 29 Wijeyaratne C N, Waduge R, Arandara D et al.. Metabolic and polycystic ovary syndromes in indigenous South Asian women with previous gestational diabetes mellitus.  BJOG. 2006;  113 1182-1187
• 30 Kousta E, Cela E, Lawrence N et al.. The prevalence of polycystic ovaries in women with a history of gestational diabetes.  Clin Endocrinol (Oxf). 2000;  53 501-507
• 31 Solomon C G, Hu F B, Dunaif A et al.. Menstrual cycle irregularity and risk for future cardiovascular disease.  J Clin Endocrinol Metab. 2002;  87 2013-2017
• 32 Wijeyaratne C N, Nirantharakumar K, Balen A H, Barth J H, Sheriff R, Belchetz P E. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity?.  Clin Endocrinol (Oxf). 2004;  60 560-567
• 33 Escobar-Morreale H F, Luque-Ramírez M, San Millán J L. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome.  Endocr Rev. 2005;  26 251-282
• 34 Crosignani P G, Nicolosi A E. Polycystic ovarian disease: heritability and heterogeneity.  Hum Reprod Update. 2001;  7 3-7
• 35 Babu K A, Rao K L, Kanakavalli M K, Suryanarayana V V, Deenadayal M, Singh L. CYP1A1, GSTM1 and GSTT1 genetic polymorphism is associated with susceptibility to polycystic ovaries in South Indian women.  Reprod Biomed Online. 2004;  9 194-200
• 36 Pasquali R, Casimirri F. The impact of obesity in hyperandrogenism and polycystic ovary syndrome in premenopausal women.  Clin Endocrinol (Oxf). 1993;  39 1-16
• 37 Hartz A J, Barboriak P N, Wong A, Katayama K P, Rimm A A. The association of obesity with infertility and related menstural abnormalities in women.  Int J Obes. 1979;  3 57-73
• 38 Chang R J, Nakamura R M, Judd H L, Kaplan S A. Insulin resistance in nonobese patients with polycystic ovarian disease.  J Clin Endocrinol Metab. 1983;  57 356-359
• 39 ESHRE/ASRM . ESHRE/ASRM Rotterdam Consensus Meeting Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).  Hum Reprod. 2004;  19 41-47
• 40 Ajayi R, Ogunmokun A. The importance of diagnosing polycystic ovary syndrome. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 38-45
• 41 Atabekoglu C S, Arici A. Pharmacologic treatment of polycystic ovary syndrome in the reproductive years. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 246-268
• 42 Wiegratz I, Kutschera E, Lee J H et al.. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins.  Contraception. 2003;  67 361-366
• 43 Guido M, Romualdi D, Giuliani M et al.. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.  J Clin Endocrinol Metab. 2004;  89 2817-2823
• 44 Rosen M P, Breitkopf D M, Nagamani M. A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris.  Am J Obstet Gynecol. 2003;  188 1158-1160
• 45 Farquhar C, Lee O, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.  Cochrane Database Syst Rev. 2003;  4 CD000194
• 46 Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.  J Clin Endocrinol Metab. 2003;  88 4116-4123
• 47 Morin-Papunen L C, Koivunen R M, Ruokonen A, Martikainem H K. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.  Fertil Steril. 1998;  69 691-696
• 48 Allahbadia G N, Agrawal R. Clomiphene citrate for ovulation induction in women with polycystic ovary syndrome. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 357-365
• 49 ESHRE Capri Workshop Group . Monoovulatory cycles: a key goal in profertility programmes.  Hum Reprod Update. 2003;  9 263-274
• 50 Branigan E F, Estes M A. Treatment of chronic anovulation resistant to clomiphene citrate (CC) by using oral contraceptive ovarian suppression followed by repeat CC treatment.  Fertil Steril. 1999;  71 544-546
• 51 Mitwally M FM, Casper R F. The development, mechanism of action and use of aromatase inhibitors for ovulation induction in polycystic ovary syndrome. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 346-356
• 52 Fleming R, Sattar N. Should patients with polycystic ovary syndrome be treated with metformin?. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 277-289
• 53 Knowler W C, Barrett-Connor E, Fowler S E et al.. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
• 54 Ayup S H, Vega P G, Halliscak R S et al.. Insulin-sensitizing drugs in the treatment of women with PCOS - the promise of metformin. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 297-305
• 55 Kriplani A, Agarwal N. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.  J Reprod Med. 2004;  49 361-367
• 56 Harborne L R, Sattar N, Norman J E, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses.  J Clin Endocrinol Metab. 2005;  90 4593-4598
• 57 Lord J M, Flight I H, Norman R J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis.  BMJ. 2003;  327 951-953
• 58 Palomba S, Orio Jr F, Falbo A et al.. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2005;  90 4068-4074
• 59 De Leo V, Marca A, Ditto A, Morgante G, Cionci A. Effects of metformin on gonadotropin-induced ovulation in women with PCOS.  Fertil Steril. 1999;  72 282-285
• 60 Yarali H, Yildiz B O, Demirol A et al.. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial.  Hum Reprod. 2002;  17 289-294
• 61 Christin-Maitre S, Hugues J N. Recombinant FSH Study Group. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome.  Hum Reprod. 2003;  18 1626-1631
• 62 Homburg R, Levy T, Berkovitz D. Gonadotropin releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome.  Fertil Steril. 1993;  59 527-531
• 63 Asia Pacific Cohort Studies Collaboration . The burden of overweight and obesity in the Asia-Pacific region.  Obes Rev. 2007;  8 191-196
• 64 Palep-Singh M, Picton H M, Vrotsou K, Maruthini D, Balen A H. South Asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts.  Eur J Obstet Gynecol Reprod Biol. 2007;  134 202-207
• 65 Xita N, Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies.  J Clin Endocrinol Metab. 2006;  91 1660-1666
• 66 Tuomilehto J, Lindstrom J, Eriksson J G et al.. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
• 67 Kiddy D S, Hamilton-Fairley D, Bush A et al.. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.  Clin Endocrinol (Oxf). 1992;  36 105-111
• 68 Piacquadio D J, Rad F S, Spellman M C, Hollenbach K A. Obesity and female androgenic alopecia: a cause and an effect?.  J Am Acad Dermatol. 1994;  30 1028-1030
• 69 Clark A M, Thornley B, Tomlinson L, Galletley C, Norman R J. Weight loss in obese infertile women 0results in improvement in reproductive outcome for all forms of fertility treatment.  Hum Reprod. 1998;  13 1502-1505
• 70 Daskalopoulou S S, Mikhailidis D P, Elisaf M. Prevention and treatment of the metabolic syndrome.  Angiology. 2004;  55 589-612
• 71 Poongothai S, Karkuzhali K, Sharadha J, Deepa R, Mohan V. Evaluation of safety and efficacy of Hyponidd, an Ayurvedic compound: a double blind, placebo controlled study in type 2 diabetic patients with secondary failure to oral drugs.  Int J Diab Dev Ctries. 2002;  22 19-27
• 72 Stanley P, Prince M, Menon V P. Hypoglycaemic and other related actions of Tinospora cordifolia roots in alloxan-induced diabetic rats.  J Ethnopharmacol. 2000;  70 9-15
• 73 Shanmugasundaram E R, Rajeswari G, Baskaran K et al.. Use of Gymnema Sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus.  J Ethnopharmacol. 1990;  30 281-294
• 74 Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram E R. Antidiabetic effect of a leaf extract from Gymnema Sylvestre in non-insulin-dependent diabetes mellitus patients.  J Ethnopharmacol. 1990;  30 295-300
• 75 Persaud S J, Al-Majed H, Raman A, Jones P M. Gymnema Sylvestre stimulates insulin release in vitro by increased membrane permeability.  J Endocrinol. 1999;  163 207-212
• 76 Indian Council of Medical Research (ICMR) Collaboration Centre . Flexible dose open trial of Vijayasar in cases of newly-diagnosed non-insulin-dependent diabetes mellitus.  Indian J Med Res. 1998;  108 24-29
• 77 Lodha R, Bagga A. Traditional Indian systems of medicine.  Ann Acad Med Singapore. 2000;  29 37-41
• 78 Leatherdale B A, Panesar R K, Singh G, Atkins T W, Bailey C J, Bignell A H. Improvement in glucose tolerance due to Momordica charantia (Karela).  Br Med J (Clin Res Ed). 1981;  282 1823-1824
• 79 Kedar P, Chakrabarti C H. Effects of Jambolan seed treatment on blood sugar, lipids and urea on steptozocin induced diabetes in rabbits.  Indian J Physiol Pharmacol. 1983;  27 135-140
• 80 Bopanna K N, Kannan J, Gadgil S, Balraman R, Rathod S P. Antidiabetic and antihyperlipaemic effects of neem seed kernel powder on alloxan diabetic rabbits.  Indian J Pharmacol. 1997;  29 162-167
• 81 Babu P S, Stanely Mainzen Prince P. Antihyperglycaemic and antioxidant effect of hyponidd, an ayurvedic herbomineral formulation in streptozotocin-induced diabetic rats.  J Pharm Pharmacol. 2004;  56 1435-1442
• 82 Seshaiah V, Sundaram A, Balaji V, Moses A. Role of Hyponidd in the treatment of noninsulin dependent diabetes mellitus.  Indian Journal of Clinical Practice. 1998;  8 1-5
• 83 Allahbadia G N, Kadam K S, Gandhi G N, Arora S, Virk S, Kaur K. To study the efficacy and tolerability of a traditional Indian drug containing D-chiro-inositol versus metformin in hyperinsulinemic PCOS subjects.  Fertil Steril. 2006;  86 S461
• 84 Sheikhha M H, Kalantar S M. Diagnostic criteria in polycystic ovary syndrome. In: Allahbadia GN, Agrawal R Polycystic Ovary Syndrome. Kent, UK; Anshan Publishers 2006: 27-32
• 85 Fleming R, Harborne L, MacLaughlin D T et al.. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment.  Fertil Steril. 2005;  83 130-136
• 86 Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome.  BJOG. 2006;  113 1148-1159
• 87 Misra A, Misra R, Wijesuriya M, Banerjee D. The metabolic syndrome in South Asians: continuing escalation & possible solutions.  Indian J Med Res. 2007;  125 345-354
• 88 Vikram N K, Misra A, Pandey R M et al.. Anthropometry and body composition in northern Asian Indian patients with type 2 diabetes: receiver operating characteristics (ROC) curve analysis of body mass index with percentage body fat as standard.  Diabetes Nutr Metab. 2003;  16 32-40